Skip to main content
OpenTrials
Completed

NCT Number: NCT01841515

Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug

Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The investigators designed a prospective study to evaluate the effect of desmopressin on platelet function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who were taking antiplatelet drugs.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bleeding Arrhythmias, Cardiac Cardiac Conduction System Disease Cardiovascular Diseases Dyspnea Heart Diseases Hemorrhage Pathologic Processes Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory Tachycardia

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Asan Medical Center

Seoul, Songpa-gu, 138-736, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult uremic patients with one or more antiplatelet medication,
  • prolonged collagen/epinephrine (CEPI) closure time,
  • need for emergent hemodialysis and
  • subsequent catheter insertion

Exclusion criteria

  • acute coronary syndrome,
  • hemophilia, and nephrogenic diabetes insipidus,
  • allergy against desmopressin

Treatment and study plan

Desmopressin administration

Drug

Primary outcomes

  1. collagen-epinephrine closure time

    Time frame: 1 hour

    In vitro closure time (CT), measured using a platelet function analyzer (PFA)-100, is a relatively new tool for investigation of primary hemostasis. This system has been shown to be efficacious in evaluating abnormalities of primary hemostasis.

Secondary outcomes

  1. Bleeding after procedure

    Time frame: 1-4 hr after procedure

    we observe incidence of bleeding complication after procedure

Sponsors and collaborators

Lead sponsor

University of Ulsan

Other

Registry information

Official study title

Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Agent Who Need Emergent Temporary Catheter Insertion for Hemodialysis

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Apr 26, 2013
Registry last updated
May 13, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.